|
|
|
 |
| Updated 07.10.08 |
|
DERP Reports and Key Questions
| |
HRC Report
|
Executive Summary
|
| Angiotensin II Receptor Antagonists or AIIRA |
|
|
| Antidepressants |
|
|
| Antiemetics or NAE |
|
|
| Antiepileptic or AP |
|
|
| Attention Deficit Hyperactivity Disorder or ADHD |
|
|
| Atypical Antipsychotics |
|
|
| Autism or ASD |
|
|
| Beta 2 Agonists or B2 |
|
|
| Beta Blocker or BB |
|
|
| Calcium Channel Blockers or CCB |
|
|
| Combination Products for Type 2 DM & Hyperlipidemia or FDCP |
|
|
| Hormone Replacement Therapy - HRT |
|
|
| Inhaled Corticosteroid or ICS |
|
|
| Insomnia |
|
|
| Long-acting Analgesics for Non-cancer Pain or OPIOID |
|
|
|
Multiple Sclerosis or MS
|
|
|
| Newer Antiplatelet or AP |
|
|
| Neuropathic Pain |
|
|
| Non-steroidal Anti-inflammatory Drugs or NSAIDS |
|
|
| Obesity, Surgical |
|
|
| Obesity, Medical |
|
|
| Oral Hypoglycemics or OH |
|
|
| Over Active Bladder or OAB |
|
|
| Peginterferons for Hepatitis C |
|
|
| Proton Pump Inhibitor or PPI |
|
|
| Skeletal Muscle Relaxers or SMR |
|
|
| STATIN |
|
|
| Targeted Immune Modulators or TIM |
|
|
| Thiazolidinediones or TZD |
|
|
| TRIPTAN |
|
|
|
|
|
|
